HIV纳米抗体的研究进展  

Research progress of HIV nanobodies

作　　者：王志明[1] 王雪[1] 贾寅星 杨立霞[1] 

机构地区：[1]华北制药集团新药研究开发有限责任公司抗体药物研制国家重点实验室,石家庄050015

出　　处：《免疫学杂志》2013年第9期808-812,共5页Immunological Journal

基　　金：国家973项目(2012CB724502)

摘　　要：纳米抗体因为其独特的性质和作用机理,在治疗性单克隆抗体中备受重视,纳米抗体药物呈现出良好的发展势头,关于HIV纳米抗体的研究也处于起步阶段。本文介绍4类在研的HIV纳米抗体:HIV gp120纳米抗体、HIV Rev纳米抗体、HIV Nef纳米抗体、HIV CXCR4纳米抗体。体外实验中,它们在对抗HIV感染、增殖、调控等方面具有强大的作用。虽然基础研究刚刚开始,但HIV纳米抗体无疑为艾滋病的治疗提供了更多的选择,为新的抗HIV药物的研究提供了机遇。As a kind of therapeutic monoclonal antibodies, nanobodies possess unique characteristics and mechanism of action. More and more research has focused on the nanobodies in recent years, and HIV nanobodies＇ research is one of them. In this paper, we reviewed 4 types of HIV nanobodies： HIV gpl20 nanobodies, HIV Rev nanobodies, HIV Nef nanobodies and HIV CXCR4 nanobodies, which strongly against in vitro HIV infection, proliferation, regulation, etc. Although the basic research is only just beginning, it is no doubt that HIV nanobodies would provide more choices for the treatment of AIDS and new opportunities for the development of new anti-HIV drugs.

关 键 词：纳米抗体 人类免疫缺陷病毒 艾滋病 

分 类 号：R446.6[医药卫生—诊断学]